Immunotherapy drug for prostate cancer
Prostate cancer is the most common cancer in males, globally. According to the National Cancer Control Program in 2010 in Sri Lanka, the prevalence of prostate cancer is as follows:
|Age range (years)||Number of cancer cases||Number of prostate cancer cases|
|65 and above||2949||12.4|
According to a trial led by a team at the Institute of Cancer Research and the Royal Marsden Hospital London proved that an immunotherapy drug has shown positive results, however, will not work for all the patients. It was further, stated that 10-15% of the patients responded to the drug and its efficacy can be determined only on terminal cancer.